ID

31211

Description

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00112060

Link

https://clinicaltrials.gov/show/NCT00112060

Keywords

Versions (1)
  1. 7/29/18 7/29/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 29, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small-Cell Lung Carcinoma NCT00112060

English

Eligibility Non-Small-Cell Lung Carcinoma NCT00112060

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age ≥ 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
histologically or cytologically confirmed nsclc which is stage iii or stage iv, or recurrent disease, and failed therapy with a standard first line (phase i/ii) as well as second line chemotherapy regimen (phase i), or be intolerant of standard chemotherapy. receipt of one additional prior chemotherapy regimen for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant is allowable. a prior epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tk) antagonist is allowable (phase ii).
Description

Non-Small Cell Lung Carcinoma TNM clinical staging | Recurrent disease | First line treatment Standard failed | Second line Chemotherapy failed | Standard Chemotherapy intolerant | Prior Chemotherapy Neoadjuvant | Chemotherapy, Adjuvant | Epidermal growth factor receptor inhibitor

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C3258246
UMLS CUI [2]
C0277556
UMLS CUI [3,1]
C1708063
UMLS CUI [3,2]
C1442989
UMLS CUI [3,3]
C0231175
UMLS CUI [4,1]
C1710038
UMLS CUI [4,2]
C0392920
UMLS CUI [4,3]
C0231175
UMLS CUI [5,1]
C1442989
UMLS CUI [5,2]
C0392920
UMLS CUI [5,3]
C0231200
UMLS CUI [6,1]
C1514457
UMLS CUI [6,2]
C0600558
UMLS CUI [7]
C0085533
UMLS CUI [8]
C1443775
asymptomatic or treated brain metastases (including steroids) if last therapy was received > 4 weeks from study entry and is deemed by the investigator to have a low likelihood of rapid deterioration.
Description

Metastatic malignant neoplasm to brain Asymptomatic | Metastatic malignant neoplasm to brain Treated | Steroids

Data type

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231221
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C1522326
UMLS CUI [3]
C0038317
ecog performance status 0 - 2.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate organ function and bone marrow reserve.
Description

Organ function | Bone Marrow Mature Neutrophils Present Adequate

Data type

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2,1]
C0005953
UMLS CUI [2,2]
C1708947
UMLS CUI [2,3]
C0205411
use of appropriate contraceptive method.
Description

Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0700589
signed patient informed consent.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
investigational agents within 30 days prior to day 1 of study.
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
known symptomatic or uncontrolled brain metastases.
Description

Metastatic malignant neoplasm to brain Symptomatic | Metastatic malignant neoplasm to brain Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C0205318
uncontrolled intercurrent illness.
Description

Comorbidity Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
known human immunodeficiency virus (hiv), hepatitis a, b, c, d and e.
Description

HIV Infection | Hepatitis A | Hepatitis B | Hepatitis C | Hepatitis D Infection | Hepatitis E

Data type

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019159
UMLS CUI [3]
C0019163
UMLS CUI [4]
C0019196
UMLS CUI [5]
C0011226
UMLS CUI [6]
C0085293
patient has uncontrolled pleural effusions.
Description

Pleural effusion Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0032227
UMLS CUI [1,2]
C0205318
patient has received nitrosoureas or mitomycin-c within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry.
Description

Nitrosoureas | Mitomycin | Chemotherapy | Therapeutic radiology procedure

Data type

boolean

Alias
UMLS CUI [1]
C0028210
UMLS CUI [2]
C0002475
UMLS CUI [3]
C0392920
UMLS CUI [4]
C1522449
Back to the top of the page

Similar models

Eligibility Non-Small-Cell Lung Carcinoma NCT00112060

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma TNM clinical staging | Recurrent disease | First line treatment Standard failed | Second line Chemotherapy failed | Standard Chemotherapy intolerant | Prior Chemotherapy Neoadjuvant | Chemotherapy, Adjuvant | Epidermal growth factor receptor inhibitor
Item
histologically or cytologically confirmed nsclc which is stage iii or stage iv, or recurrent disease, and failed therapy with a standard first line (phase i/ii) as well as second line chemotherapy regimen (phase i), or be intolerant of standard chemotherapy. receipt of one additional prior chemotherapy regimen for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant is allowable. a prior epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tk) antagonist is allowable (phase ii).
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0277556 (UMLS CUI [2])
C1708063 (UMLS CUI [3,1])
C1442989 (UMLS CUI [3,2])
C0231175 (UMLS CUI [3,3])
C1710038 (UMLS CUI [4,1])
C0392920 (UMLS CUI [4,2])
C0231175 (UMLS CUI [4,3])
C1442989 (UMLS CUI [5,1])
C0392920 (UMLS CUI [5,2])
C0231200 (UMLS CUI [5,3])
C1514457 (UMLS CUI [6,1])
C0600558 (UMLS CUI [6,2])
C0085533 (UMLS CUI [7])
C1443775 (UMLS CUI [8])
Metastatic malignant neoplasm to brain Asymptomatic | Metastatic malignant neoplasm to brain Treated | Steroids
Item
asymptomatic or treated brain metastases (including steroids) if last therapy was received > 4 weeks from study entry and is deemed by the investigator to have a low likelihood of rapid deterioration.
boolean
C0220650 (UMLS CUI [1,1])
C0231221 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C0038317 (UMLS CUI [3])
ECOG performance status
Item
ecog performance status 0 - 2.
boolean
C1520224 (UMLS CUI [1])
Organ function | Bone Marrow Mature Neutrophils Present Adequate
Item
adequate organ function and bone marrow reserve.
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C1708947 (UMLS CUI [2,2])
C0205411 (UMLS CUI [2,3])
Contraceptive methods
Item
use of appropriate contraceptive method.
boolean
C0700589 (UMLS CUI [1])
Informed Consent
Item
signed patient informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Investigational New Drugs
Item
investigational agents within 30 days prior to day 1 of study.
boolean
C0013230 (UMLS CUI [1])
Metastatic malignant neoplasm to brain Symptomatic | Metastatic malignant neoplasm to brain Uncontrolled
Item
known symptomatic or uncontrolled brain metastases.
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Comorbidity Uncontrolled
Item
uncontrolled intercurrent illness.
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
HIV Infection | Hepatitis A | Hepatitis B | Hepatitis C | Hepatitis D Infection | Hepatitis E
Item
known human immunodeficiency virus (hiv), hepatitis a, b, c, d and e.
boolean
C0019693 (UMLS CUI [1])
C0019159 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0019196 (UMLS CUI [4])
C0011226 (UMLS CUI [5])
C0085293 (UMLS CUI [6])
Pleural effusion Uncontrolled
Item
patient has uncontrolled pleural effusions.
boolean
C0032227 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Nitrosoureas | Mitomycin | Chemotherapy | Therapeutic radiology procedure
Item
patient has received nitrosoureas or mitomycin-c within 6 weeks or other chemotherapy or radiation therapy within 3 weeks before study entry.
boolean
C0028210 (UMLS CUI [1])
C0002475 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial